HIV-1 subtypes differ in disease progression. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


HIV-1 subtypes differ in disease progression.

Conf Adv AIDS Vaccine Dev. 1997 May 4-7;:24. Unique Identifier : AIDSLINE MED/97927016
Kanki P; Hamel D; Sankale JL; Hsieh CC; Thior I; Essex M; Mboup S; Harvard AIDS Institute, Boston, MA. Fax: (617) 432-3575.

Abstract: Much of our knowledge of HIV-1 pathogenesis comes from the developed world, where HIV infection is almost exclusively due to subtype B. The recognition of the different HIV-1 subtypes, have led many to question whether properties of HIV-1 infection and its consequences as a whole can be generalized among different subtypes. From 1985 to 1995, a prospective study of registered female sex workers has described the introduction and dynamics of subtypes A, C, D, and G in 54 women with seroincident infection. In clinical follow-up, the AIDS-free survival curves were distinct by HIV subtype (p value =0.02). The predominant subtype A (68%) showed a 92% probability of AIDS-free time at 5 years post infection, a multivariate cox regression model confirmed a significantly lower hazard ratio for the development of AIDS hazard ratio= 0.12; 95%CI= 0.025 to 0.56, p value = 0.007). This study demonstrates that different HIV-1 subtypes may differ in their progression to AIDS and suggests that the diversity of HIV-1 pathogenesis can be resolved at the level of the genetic subtype.
Keywords: *Acquired Immunodeficiency Syndrome/VIROLOGY *HIV Infections/VIROLOGY *HIV-1/CLASSIFICATIONKWDacquiredimmunodeficiencysyndrome/virologyKWDhivinfections/virologyKWDhiv-1/classification
971130
M97B1202

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .